CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Bioventures Opportunities G. Yk Sells 3,250,000 Shares

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $0.10, for a total value of $325,000.00. Following the completion of the transaction, the insider now directly owns 22,620,783 shares in the company, valued at approximately $2,262,078.30. The trade was a 12.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

CERo Therapeutics Price Performance

Shares of NASDAQ CERO traded up $0.19 during mid-day trading on Friday, reaching $0.37. The company’s stock had a trading volume of 701,649,063 shares, compared to its average volume of 18,424,012. CERo Therapeutics Holdings, Inc. has a 1-year low of $0.06 and a 1-year high of $12.80. The stock has a 50-day moving average of $0.10 and a two-hundred day moving average of $0.36.

CERo Therapeutics (NASDAQ:CERO) last posted its earnings results on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.